Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement

Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement with Meiji and Dong-A Socio Holdings (a parent company of Dong-A ST) to commercialize DMB-3115, a proposed biosimilar to ustekinumab, a recombinant monoclonal antibody for the treatment of autoimmune and inflammatory diseases such as plaque psoriasis, Crohn's disease and ulcerative colitis.

Under the terms of the agreement, Intas have been granted exclusive license rights to commercialize DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia. Meiji and Dong-A ST will develop and manufacture DMB-3115 and supply the product to Intas and its worldwide affiliates.

This is yet another industry first for Intas, one of the leaders in the development and commercialization of biosimilar products, who are the first Indian company to launch a biosimilar product in the EU.

"We are truly excited by this partnership, which brings together the development expertise of Meiji and Dong-A ST with the extensive commercial reach of Intas," said Vice Chairman, Mr. Binish Chudgar. "This agreement underlines our vision and commitment to increase access to life-changing medicines that can make a real difference to patient lives across the world," said Chrys Kokino, President of Accord BioPharma, Inc., the US specialty subsidiary of Intas.